Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Daiichi Sankyo to Acquire Control of Ranbaxy

publication date: Jun 11, 2008

Daiichi Sankyo, the third largest drugmaker in Japan, will buy at least a 51.1% stake in Ranbaxy of India. The two companies have vastly different business plans that they hope will complement each other: Daiichi Sankyo discovers and markets patented pharmaceuticals for the cardiovascular and cancer markets, while Ranbaxy, the largest drug firm in India, is a worldwide force in the generic drug business. Daiichi Sanko estimates it will pay between $4.6 billion and $3.4 billion, a deal that values all of Ranbaxy at $8.5 billion. More details...

Stock Symbols: (TSE: 4568.JP) (NSE/BSE: Ranbaxy/500359) (NYSE: PFE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital